CY1111881T1 - Υδατικη φαρμακοτεχνικη μορφη του 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλο-βενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκου οξεος - Google Patents

Υδατικη φαρμακοτεχνικη μορφη του 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλο-βενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκου οξεος

Info

Publication number
CY1111881T1
CY1111881T1 CY20111100857T CY111100857T CY1111881T1 CY 1111881 T1 CY1111881 T1 CY 1111881T1 CY 20111100857 T CY20111100857 T CY 20111100857T CY 111100857 T CY111100857 T CY 111100857T CY 1111881 T1 CY1111881 T1 CY 1111881T1
Authority
CY
Cyprus
Prior art keywords
oxy
amino
phenylthio
carboxyl
benzyl
Prior art date
Application number
CY20111100857T
Other languages
English (en)
Inventor
Bernd KÜHN
Daniel Wagner
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1111881T1 publication Critical patent/CY1111881T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε υδατική φαρμακοτεχνική μορφή, η οποία περιέχει 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλοβενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκό οξύ ή άλας αυτού. Ειδικότερα, η παρούσα εφεύρεση αναφέρεται σε υδατική φαρμακοτεχνική μορφή, η οποία περιέχει 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλοβενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκό οξύ ή άλας αυτού και αμινο-2(υδροξυμεθυλο)-2-προπανοδιόλη-1,3 (τρομεταμόλη).
CY20111100857T 2006-07-06 2011-09-07 Υδατικη φαρμακοτεχνικη μορφη του 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλο-βενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκου οξεος CY1111881T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006031175A DE102006031175A1 (de) 2006-07-06 2006-07-06 Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
EP07764851A EP2040691B1 (de) 2006-07-06 2007-06-26 Wässrige arzneimittelformulierung von 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]- phenethyl}amino)methyl]benzoesäure

Publications (1)

Publication Number Publication Date
CY1111881T1 true CY1111881T1 (el) 2015-11-04

Family

ID=38330492

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100857T CY1111881T1 (el) 2006-07-06 2011-09-07 Υδατικη φαρμακοτεχνικη μορφη του 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλο-βενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκου οξεος

Country Status (33)

Country Link
US (1) US20100069493A1 (el)
EP (1) EP2040691B1 (el)
JP (1) JP2009542589A (el)
KR (1) KR20090031546A (el)
CN (1) CN101484154A (el)
AR (1) AR061812A1 (el)
AT (1) ATE511837T1 (el)
AU (1) AU2007271431A1 (el)
BR (1) BRPI0714012A2 (el)
CA (1) CA2656630A1 (el)
CL (1) CL2007001960A1 (el)
CO (1) CO6160303A2 (el)
CR (1) CR10550A (el)
CY (1) CY1111881T1 (el)
DE (1) DE102006031175A1 (el)
DK (1) DK2040691T3 (el)
EC (1) ECSP089023A (el)
ES (1) ES2366389T3 (el)
GT (1) GT200800310A (el)
IL (1) IL195970A0 (el)
MA (1) MA30600B1 (el)
MX (1) MX2009000012A (el)
PE (1) PE20080554A1 (el)
PL (1) PL2040691T3 (el)
PT (1) PT2040691E (el)
RU (1) RU2009103818A (el)
SI (1) SI2040691T1 (el)
SV (1) SV2009003143A (el)
TN (1) TNSN08517A1 (el)
TW (1) TW200808690A (el)
UA (1) UA94955C2 (el)
UY (1) UY30471A1 (el)
WO (1) WO2008003414A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2115213A1 (en) * 2007-02-08 2009-11-11 Dow Global Technologies Inc. Flexible conductive polymeric sheet
DE102008062689A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Modifikation I der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
DE102008062688A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Monohydrat der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
JP6189315B2 (ja) 2011-11-25 2017-08-30 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換された５−フルオロ−１ｈ−ピラゾロピリジン類を製造するための方法
KR102137517B1 (ko) * 2012-07-20 2020-07-24 바이엘 파마 악티엔게젤샤프트 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
GT200800310A (es) 2009-07-31
UA94955C2 (en) 2011-06-25
CL2007001960A1 (es) 2008-02-01
UY30471A1 (es) 2008-02-29
WO2008003414A1 (de) 2008-01-10
TW200808690A (en) 2008-02-16
EP2040691A1 (de) 2009-04-01
KR20090031546A (ko) 2009-03-26
ES2366389T3 (es) 2011-10-19
SV2009003143A (es) 2009-07-28
JP2009542589A (ja) 2009-12-03
SI2040691T1 (sl) 2011-10-28
MA30600B1 (fr) 2009-07-01
TNSN08517A1 (en) 2010-04-14
PT2040691E (pt) 2011-08-23
DK2040691T3 (da) 2011-09-26
DE102006031175A1 (de) 2008-01-10
PE20080554A1 (es) 2008-07-13
BRPI0714012A2 (pt) 2013-04-02
ATE511837T1 (de) 2011-06-15
RU2009103818A (ru) 2010-08-20
MX2009000012A (es) 2009-01-23
AU2007271431A1 (en) 2008-01-10
IL195970A0 (en) 2009-09-01
CR10550A (es) 2009-06-04
US20100069493A1 (en) 2010-03-18
PL2040691T3 (pl) 2012-01-31
ECSP089023A (es) 2009-01-30
AR061812A1 (es) 2008-09-24
CO6160303A2 (es) 2010-05-20
CN101484154A (zh) 2009-07-15
CA2656630A1 (en) 2008-01-10
EP2040691B1 (de) 2011-06-08

Similar Documents

Publication Publication Date Title
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CY1111881T1 (el) Υδατικη φαρμακοτεχνικη μορφη του 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλο-βενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκου οξεος
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
RS52108B (en) 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS
EA201100969A1 (ru) Солевые формы органического соединения
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
CY1115838T1 (el) Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους
CY1107141T1 (el) Μεθοδος για την παρασκευη της 1-(2s,3s)-2-βενζυδρυλ-ν-(5-τριτ.-βουτυλ-2-μεθοξυβενζυλ)κινουκλιδιν-3-αμινης
CR9993A (es) Formulación de suspensión de fexofenadina
BRPI0607645A2 (pt) sais de derivados de hexaidrofenantridina substituìdos com 6-heterociclila
NO20055923L (no) Farmasoytisk anvendbare salter av karboksylsyrderivater
NO20052907L (no) Sykloalkylendikarboksylsyreforbindelser som antiinflammatoriske, immunmodulatoriske og antiproliferative midler
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
CY1105790T1 (el) Νεα μεθοδος για τη συνθεση πepιντοπριλ και των φαρμακευτικως αποδεκτων αλατων αυτου
UY28375A1 (es) Agente terapéuticos
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
ECSP088374A (es) Formulacion de aerosol para inhalacion
CY1112023T1 (el) Φαρμακοτεχνικη μορφη νιτροοξυπαραγωγων των nsaids
DK1585728T3 (da) Iminosyrederivater som inhibitorer af matrix-metalloproteinaser
ATE526014T1 (de) Therapeutisches mittel gegen diabetische neuropathie
CU20080249A7 (es) Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico
EA200801209A1 (ru) Гетероароматические сульфонамидные пролекарства